These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23054209)

  • 1. The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells.
    di Iasio MG; Zauli G
    Invest New Drugs; 2013 Apr; 31(2):458-60. PubMed ID: 23054209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
    Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
    Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.
    Secchiero P; Voltan R; di Iasio MG; Melloni E; Tiribelli M; Zauli G
    Clin Cancer Res; 2010 Mar; 16(6):1824-33. PubMed ID: 20215548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
    Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
    Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.
    di Iasio MG; Norcio A; Melloni E; Zauli G
    Invest New Drugs; 2012 Dec; 30(6):2403-6. PubMed ID: 22238073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3.
    Agnoletto C; Melloni E; Casciano F; Rigolin GM; Rimondi E; Celeghini C; Brunelli L; Cuneo A; Secchiero P; Zauli G
    Oncotarget; 2014 Jun; 5(12):4347-60. PubMed ID: 24962518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.
    Zauli G; Voltan R; di Iasio MG; Bosco R; Melloni E; Sana ME; Secchiero P
    Clin Cancer Res; 2011 May; 17(9):2712-24. PubMed ID: 21367750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.
    Zauli G; di Iasio MG; Secchiero P; Dal Bo M; Marconi D; Bomben R; Del Poeta G; Gattei V
    Curr Cancer Drug Targets; 2009 Jun; 9(4):510-8. PubMed ID: 19519319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).
    Secchiero P; Barbarotto E; Tiribelli M; Zerbinati C; di Iasio MG; Gonelli A; Cavazzini F; Campioni D; Fanin R; Cuneo A; Zauli G
    Blood; 2006 May; 107(10):4122-9. PubMed ID: 16439677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
    Voltan R; Secchiero P; Corallini F; Zauli G
    Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells.
    Tisato V; Norcio A; Celeghini C; Milani D; Gonelli A; Secchiero P
    Clinics (Sao Paulo); 2014 Jan; 69(1):68-74. PubMed ID: 24473562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples.
    di Iasio MG; Addobbati R; Radillo O; Voltan R
    Invest New Drugs; 2012 Aug; 30(4):1761-5. PubMed ID: 21626114
    [No Abstract]   [Full Text] [Related]  

  • 16. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
    Voltan R; Rimondi E; Melloni E; Rigolin GM; Casciano F; Arcidiacono MV; Celeghini C; Cuneo A; Zauli G; Secchiero P
    Oncotarget; 2016 Oct; 7(43):70623-70638. PubMed ID: 27661115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
    Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
    Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
    Wang DM; Liu L; Fan L; Zou ZJ; Zhang LN; Yang S; Li JY; Xu W
    Cancer Biol Ther; 2012 Dec; 13(14):1522-8. PubMed ID: 23052131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM; Bhattacharya S; Johnson LR
    Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.
    Secchiero P; Zerbinati C; Melloni E; Milani D; Campioni D; Fadda R; Tiribelli M; Zauli G
    Neoplasia; 2007 Oct; 9(10):853-61. PubMed ID: 17971905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.